Navigation Links
Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
Date:9/18/2007

/p>

COPD is a preventable and treatable lung disease characterized by chronic airflow limitation that is not fully reversible.(5) COPD is a leading cause of death, illness, and disability in the United States, with an estimated 10 million to 24 million adults in the US living with COPD.(6)

About Aclidinium Bromide

Aclidinium bromide is a novel inhaled anticholinergic bronchodilator that is currently in phase III clinical development as a once-daily maintenance treatment for COPD.

About Forest Laboratories and Its Products

Forest Laboratories (http://www.frx.com) is a US-based pharmaceutical company dedicated to identifying, developing and delivering products that make a positive difference in peoples' lives. Forest Laboratories' growing product line includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for adults for the initial and maintenance treatment of major depressive disorder and generalized anxiety disorder; Namenda(R) (memantine HCl), an N-methyl D- aspartate (NMDA)-receptor antagonist indicated for the treatment of moderate to severe Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan medoxomil - hydrochlorothiazide), an angiotensin receptor blocker and diuretic combination product, each indicated for the treatment of hypertension; and Campral(R)* (acamprosate calcium), indicated in combination with psychosocial support for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation.

*Benicar is a registered trademark of Daiichi Sankyo, Inc., and Campral is a registered trademark of Merck Sante s.a.s., subsidiary of Merck KGaA, Darmstadt, Germany.

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These sta
'/>"/>

SOURCE Forest Laboratories
Copyright©2007 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...swire-FirstCall/--CordBloodAmerica,Inc.(OTCBulleti...tioncompany( http://www.cordblood-america.com )foc...iologicalinsurancepolicy,tofamiliesnationwideandin...nterviewwithCEOandco-founderMatthewSchisslerisnowa...p.tv/file/2875811 . ,, Intheinterview,Mr.Schiss...
(Date:11/23/2009).../PRNewswire-FirstCall/--Pharmasset,Inc.(Nasdaq: VR...itspartnerRoche(SWX:ROG.VX;RO.S,OTCQX:RHHBY),willc...eongoingphase2btrialofRG7128,afirst-in-classnucleo...nichepatitisCvirus(HCV)infection.Thedecisionwasrea...ringCommittee(DMC)ofallavailablesafetydatafromthef...
(Date:11/23/2009)...PRNewswire-FirstCall/--RaptorPharmaceuticalCorp.("...edresultsfromaPhase2bclinicaltrialofitsproprietary...)inpatientswithnephropathiccystinosis("cystinosis"...nDiego("UCSD")GeneralClinicalResearchCenter,evalua...dynamicsofasingledoseofDRCysteamineinninecystinosi...
Breaking Medicine Technology:Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 2Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 3Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 5FDA Panel Weighs Approving HPV Vaccine for Males 56544 1FDA Panel Weighs Approving HPV Vaccine for Males 56544 2FDA Panel Weighs Approving HPV Vaccine for Males 56544 3CONCERTA 28R 29 28methylphenidate HCI 29 LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 56540 1CONCERTA 28R 29 28methylphenidate HCI 29 LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 56540 2CONCERTA 28R 29 28methylphenidate HCI 29 LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 56540 3CONCERTA 28R 29 28methylphenidate HCI 29 LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 56540 4CONCERTA 28R 29 28methylphenidate HCI 29 LAUNCHES MOBILE WEB EXPERIENCE TO PROVIDE TOOLS AND SUPPORT FOR ADHD AWARENESS 56540 5Cash For Crows Feet Program Offers Effective and Affordable Laser Skin Treatments 56536 1Cash For Crows Feet Program Offers Effective and Affordable Laser Skin Treatments 56536 2
... Efficacy of Treating Patients with ...nd YONGIN-SI, South Korea, July 22 ,Jennerex, Inc....South,Korean partner Green Cross Corp., announced ...trial of its first-in-class lead product JX-594,de... resulted in clear,anti-cancer efficacy in patient...
...rapy and pegylated enzyme produces significantl... - - Pegylated enzyme well tolera...Inc. (Nasdaq: HALO ), a biopharmaceutical company... the extracellular matrix, today,announced the pre... data,for its pegylated-rHuPH20 enzyme (PEGPH20) a...
Other Medicine Technology:Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 2Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 3Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 2Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 3Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 4Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models 5
(Date:11/23/2009)... Older males saw their odds drop by 63 percent wi..., MONDAY, Nov. 23 (HealthDay News) -- Moderate-to... or tennis may help reduce stroke risk in older me...tudy included almost 3,300 men and women, average ...ine years. During that time, there were 238 stroke...
(Date:11/23/2009)... Dr. Bernadine Healy, first woman to head the age...DAY, Nov. 23 (HealthDay News) -- The fallout from ...n delay the start of routine mammogram testing for...e U.S. National Institutes of Health advising wome...powerfully ignore them, because unequivocally this...
(Date:11/23/2009)... ,, CENTERCITY,Minn.,Nov.23/PRNewswire/--Haz...treatmentcenter,todayannouncedtheleadershipteamfor...bedfacilityinNaplesisscheduledtoopeninlateMarch201...sforadults,includingafullarrayoffamilyandoutpatien...ecutivedirectorofHazelden,sfacilityinNaples,withBr...
(Date:11/23/2009)... ,, $4Million Alliance ProgramSupportsFut...nshipGuideAvailableat www.Allia n ceS ...ire-USNewswire/--"Mr.President,youcancountusin.Wit...lianceisproudtobeapartofEducatetoInnovate,"saidAdo...ceforHispanicHealth,afterattendingaWhiteHousemeeti...
(Date:11/23/2009)... ,, TUCSON,Ariz.,Nov.23/PRNewswire/--Cortiva...apyWorkshoponSunday,Dec.6from1-3p.m.attheschool,s6...ortunityforparticipantstolearnandpracticebasicmass...dCortivaInstituteTucsonisgrowingrightalongwithit,"...n. ,, Infact,theU.S.DepartmentofLabor,s2009-201...
Breaking Medicine News(10 mins):Health News:Vigorous Exercise Cuts Stroke Risk for Men, Not Women 2Health News:Women Should Ignore New Mammogram Guideline, Ex-NIH Chief Says 2Health News:Women Should Ignore New Mammogram Guideline, Ex-NIH Chief Says 3Health News:Hazelden Names Leadership Team for New Recovery Center in Naples, Florida 2Health News:Alliance Joins President Obama at White House in Commitment to Science, Technology, Engineering, and Math (STEM) Education 2Health News:Cortiva Institute To Host Workshop, Hands-On Opportunity for Prospective Students 2
... Illinois will host a first-of-its-,kind celebrati...s and,friends. The BIG Night Out - Indulgence for...om 6:30 p.m. to 10:00 p.m. in the Great Hall of Ch...olates,scrumptious hors d,ouevres and martinis mad...
... /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals,...t signed amended,agreements with Smith & Nephew wo...icoat(TM) dressings with SILCRYST(TM) nanocrystall...o grant,NUCRYST exclusive manufacturing rights, pl...
... Oct. 1 UTC Power, a,United Technologies Corp. (N...ed Dome- Tech Group, a national energy consulting ...y. Financial terms were not disclosed. Dome-Tech ...d carbon footprint reduction, smart energy,procure...
...Capabilities that Help Patients Achieve Optimum He....,(Nasdaq: VTIV ) today announced that it has lau...Outcomes, with a focus on helping pharmaceutical,c... wins -,the healthcare providers, the pharmaceutic...
... Increasing New Jersey Life Sciences Jobs With ... PARSIPPANY, N.J., Oct. 1 Daiichi Sankyo, Inc. ha...s and rapidly increasing its,staffing since 2002 t...cal companies experiencing steady and sustained,gr...
...ty Awareness Month, WHITE PLAINS, N.Y., Oct. 1 M...h the March of Dimes to help give,every baby their...ternity,a national sponsor of the March of Dimes P...to save babies from,premature birth. "We are plea...
Other Medicine News:Health News:Y-ME Illinois Hosts the First-Ever 'BIG Night Out' - Indulgence for a Cause 2Health News:NUCRYST and Smith & Nephew Revise Agreements 2Health News:NUCRYST and Smith & Nephew Revise Agreements 3Health News:NUCRYST and Smith & Nephew Revise Agreements 4Health News:NUCRYST and Smith & Nephew Revise Agreements 5Health News:NUCRYST and Smith & Nephew Revise Agreements 6Health News:NUCRYST and Smith & Nephew Revise Agreements 7Health News:UTC Power Acquires Dome-Tech Group 2Health News:inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes 2Health News:inVentiv Health Launches Fourth Business Segment: inVentiv Patient Outcomes 3Health News:Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 2Health News:Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 3Health News:Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 4Health News:Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 5Health News:Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 6Health News:Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 7Health News:Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firms Downsize 8Health News:Motherhood(R) Maternity Joins March of Dimes to Give Babies a Healthy Start in Life 2
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
Medicine Products: